Therefore, compared with prior meta-analyses, this meta-analysis provided the updated information regarding long-term efficacy and safety of first-line PD-1 inhibitors plus chemotherapy in patients with advanced HER2-negative GC. Here, ERBB2 is linked to gastric cancer.